Activated Charcoal is named as an intervention in 3 current clinical trials in our Canada, UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Israel and Egypt registers. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Sanofi (1). The most-studied condition is Multiple Sclerosis.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Activated CHARcoal in Poisoned Patient - Pilot Trial
NCT05471479 · ClinicalTrials.gov ↗ · Charcoal, Decontamination, Poisoning
|
Phase 4 | Recruiting | Laval University | Canada |
|
Activated Charcoal Use in Chronic Kidney Disease Patients
NCT06906874 · ClinicalTrials.gov ↗ · End Stage Renal Disease (ESRD), CKD 5D, Hemodialysis, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder
|
Phase 2 | Recruiting | Mansoura University | Egypt |
|
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473 · ClinicalTrials.gov ↗ · Multiple Sclerosis
|
Phase 3 | Active, closed | Sanofi | UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Israel |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
| Lead sponsor | Trials |
|---|---|
| Sanofi | 1 |
| Laval University | 1 |
| Mansoura University | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our Canada, UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Portugal, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Israel and Egypt registers name Activated Charcoal as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in Canada and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Sanofi (1), Laval University (1) and Mansoura University (1). The number in brackets is how many trials each organisation leads.
The registers we track list 1 entry for Activated Charcoal: US FDA: resolved. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Activated Charcoal works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Activated Charcoal works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Activated Charcoal (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.